Literature DB >> 6383454

A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantation.

H A Blacklock, F Katz, R Michalevicz, G R Hazlehurst, L Davies, H G Prentice, A V Hoffbrand.   

Abstract

Using anti-A and anti-B blood group monoclonal antibodies and fluorescent activated cell sorting of human bone marrow, A (or B) blood group antigen was shown to be on 5.2 +/- 5.9 (mean +/- SD) % of CFU-GEMM and 12.5 +/- 19.6% of the erythroid burst forming cells (designated BFU-GEMM) as defined by the mixed colony assay, and 49.5 +/- 20% of the BFU-E and 83.5 +/- 9.9% of the CFU-E as defined by the erythroid colony assay. This antigen expression on the BFU-GEMM is consistent with the concept that erythroid bursts stimulated by leucocyte conditioned medium are less mature, and are closer in development to the pluripotent stem cell than the BFU-E. These results help to explain the delayed erythropoiesis, and perhaps impaired engraftment of all cell lineages, that may occur in some recipients of ABO incompatible bone marrow transplants with persistent and high anti-A titres.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6383454     DOI: 10.1111/j.1365-2141.1984.tb06085.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.

Authors:  Gordana Tomac; Ines Bojanić; Sanja Mazić; Ivana Vidović; Mirela Raos; Branka Golubić Ćepulić; Ranka Serventi Seiwerth; Jadranka Kelečić; Boris Labar
Journal:  Blood Transfus       Date:  2017-04-19       Impact factor: 3.443

2.  Immunoadsorption for removal of anti-A and anti-B blood group antibodies in ABO-incompatible bone marrow transplantation.

Authors:  B Osterwalder; A Gratwohl; C Nissen; B Speck
Journal:  Blut       Date:  1986-11

3.  Blood transfusion in marrow graft recipients.

Authors:  P Pihlstedt; T Paulin; B Sundberg; B Nilsson; O Ringdén
Journal:  Ann Hematol       Date:  1992-08       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.